CN115463246A - 一种血管栓塞剂及其制备方法与应用 - Google Patents
一种血管栓塞剂及其制备方法与应用 Download PDFInfo
- Publication number
- CN115463246A CN115463246A CN202211019192.1A CN202211019192A CN115463246A CN 115463246 A CN115463246 A CN 115463246A CN 202211019192 A CN202211019192 A CN 202211019192A CN 115463246 A CN115463246 A CN 115463246A
- Authority
- CN
- China
- Prior art keywords
- mixed solution
- vascular embolization
- agent
- embolization agent
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000010102 embolization Effects 0.000 title claims abstract description 147
- 230000002792 vascular Effects 0.000 title claims abstract description 132
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 171
- 239000011259 mixed solution Substances 0.000 claims abstract description 101
- -1 polyphenol compounds Chemical class 0.000 claims abstract description 36
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 24
- 239000003960 organic solvent Substances 0.000 claims abstract description 23
- 238000010790 dilution Methods 0.000 claims abstract description 21
- 239000012895 dilution Substances 0.000 claims abstract description 21
- 238000007789 sealing Methods 0.000 claims abstract description 19
- 238000001816 cooling Methods 0.000 claims abstract description 18
- 229930013930 alkaloid Natural products 0.000 claims abstract description 17
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 14
- 150000004864 1,2-dithiolanes Chemical class 0.000 claims abstract description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 145
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 23
- 229960000281 trometamol Drugs 0.000 claims description 23
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 18
- 235000019136 lipoic acid Nutrition 0.000 claims description 18
- 229960002663 thioctic acid Drugs 0.000 claims description 18
- 239000001263 FEMA 3042 Substances 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 229940033123 tannic acid Drugs 0.000 claims description 11
- 229920002258 tannic acid Polymers 0.000 claims description 11
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 9
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 9
- 235000015523 tannic acid Nutrition 0.000 claims description 9
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 8
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 8
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 8
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 4
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 claims description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 4
- 235000004883 caffeic acid Nutrition 0.000 claims description 4
- 229940074360 caffeic acid Drugs 0.000 claims description 4
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
- 229960003638 dopamine Drugs 0.000 claims description 4
- 235000004515 gallic acid Nutrition 0.000 claims description 4
- 229940074391 gallic acid Drugs 0.000 claims description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 4
- 229910001338 liquidmetal Inorganic materials 0.000 claims description 4
- 229920001690 polydopamine Polymers 0.000 claims description 4
- 235000005875 quercetin Nutrition 0.000 claims description 4
- 229960001285 quercetin Drugs 0.000 claims description 4
- 235000021283 resveratrol Nutrition 0.000 claims description 4
- 229940016667 resveratrol Drugs 0.000 claims description 4
- 239000012216 imaging agent Substances 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 2
- 235000021513 Cinchona Nutrition 0.000 claims description 2
- 241000157855 Cinchona Species 0.000 claims description 2
- 229910000846 In alloy Inorganic materials 0.000 claims description 2
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 2
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 2
- 235000010208 anthocyanin Nutrition 0.000 claims description 2
- 239000004410 anthocyanin Substances 0.000 claims description 2
- 229930002877 anthocyanin Natural products 0.000 claims description 2
- 150000004636 anthocyanins Chemical class 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000005487 catechin Nutrition 0.000 claims description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 2
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 2
- 229940074393 chlorogenic acid Drugs 0.000 claims description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 2
- 229950001002 cianidanol Drugs 0.000 claims description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 235000012754 curcumin Nutrition 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims description 2
- 229940109262 curcumin Drugs 0.000 claims description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960002179 ephedrine Drugs 0.000 claims description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 2
- 235000008696 isoflavones Nutrition 0.000 claims description 2
- FNRGIBAVNSUVAY-UHFFFAOYSA-N kottamide E Natural products C=1NC2=CC(Br)=C(Br)C=C2C=1C=CNC(=O)C(=O)NC1(C(=O)N)CSSC1 FNRGIBAVNSUVAY-UHFFFAOYSA-N 0.000 claims description 2
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000005493 rutin Nutrition 0.000 claims description 2
- 229960004555 rutoside Drugs 0.000 claims description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims 2
- MUZIZEZCKKMZRT-UHFFFAOYSA-N 1,2-dithiolane Chemical compound C1CSSC1 MUZIZEZCKKMZRT-UHFFFAOYSA-N 0.000 claims 1
- 244000240602 cacao Species 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 14
- 239000007788 liquid Substances 0.000 abstract description 9
- 210000004088 microvessel Anatomy 0.000 abstract 1
- 238000010586 diagram Methods 0.000 description 30
- 239000000499 gel Substances 0.000 description 29
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 19
- 230000003073 embolic effect Effects 0.000 description 19
- 238000003860 storage Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 229910001128 Sn alloy Inorganic materials 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 210000004204 blood vessel Anatomy 0.000 description 13
- 208000005189 Embolism Diseases 0.000 description 12
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 11
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 11
- 229960003787 sorafenib Drugs 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000001105 femoral artery Anatomy 0.000 description 10
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229910052733 gallium Inorganic materials 0.000 description 9
- RHZWSUVWRRXEJF-UHFFFAOYSA-N indium tin Chemical compound [In].[Sn] RHZWSUVWRRXEJF-UHFFFAOYSA-N 0.000 description 9
- 210000002254 renal artery Anatomy 0.000 description 9
- 239000002994 raw material Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- 229940009456 adriamycin Drugs 0.000 description 6
- 229960004679 doxorubicin Drugs 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010002329 Aneurysm Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010063544 Renal embolism Diseases 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012285 ultrasound imaging Methods 0.000 description 3
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- 240000007711 Peperomia pellucida Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000001237 Raman spectrum Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000005744 arteriovenous malformation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229960001292 cabozantinib Drugs 0.000 description 2
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 230000010109 chemoembolization Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960004836 regorafenib Drugs 0.000 description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000010108 arterial embolization Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
- 229950010048 enbucrilate Drugs 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229950007318 ozogamicin Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种血管栓塞剂及其制备方法与应用,涉及血管栓塞剂技术领域。本发明所述血管栓塞剂的制备方法包括如下步骤:(1)将1,2‑二硫戊环类化合物、多酚类化合物、生物碱溶解于有机溶剂A中,得到混合溶液A;(2)将所述混合溶液A密封后置于70℃以上的环境中反应5~12h,得到混合溶液B;(3)将所述混合溶液B冷却至室温,向其中加入有机溶剂B进行稀释,得到所述血管栓塞剂。本发明通过采用上述方法制备出了一种液体血管栓塞剂,所述血管栓塞剂具有出色的生物相容性、稳定的机械性能、优异的血管内弥散性、易输送至微血管以及形状复杂的靶血管,不粘管,可显影且无影像学伪影。
Description
技术领域
本发明涉及血管栓塞剂技术领域,尤其涉及一种血管栓塞剂及其制备方法与应用。
背景技术
血管栓塞治疗由于其创伤小、重复性高、见效快等优点,已成为临床上治疗血管性病变和肿瘤性病变的有效手段,尤其是针对出血性病变、血管畸形、动脉瘤和巴塞罗那分期(Barcelona Clinic Liver Cancer)中期的原发性肝癌。根据物理性状,可将当前临床使用的栓塞材料分为固体栓塞材料和液体栓塞材料。固体栓塞材料主要包括弹簧圈、明胶海绵颗粒和聚乙烯醇微球等。液体栓塞材料主要包括氰基丙烯酸丁酯(N-butyl-cyanoacrylate,nBCA)、Onyx(主要成分乙烯-乙烯醇共聚物和二甲基亚砜)和碘化油等。
弹簧圈在填塞过程中既易引起血管破裂,又会因血管过度扭曲而无法输送至目标部位。明胶海绵颗粒易降解,导致血管再通。聚乙烯醇微球和明胶海绵颗粒均易发生团聚,从而很难达到微血管。nBCA遇到血液迅速发生聚合反应,形成栓塞。然而,反应产物弥散性差,易与导管粘附在一起,给患者带来较大的危险。Onyx无法降解,易导致局部慢性炎症和(或)机体排斥反应。碘化油流动性较强,易导致血管再通、栓塞效果不佳,而且无法有效地装载和缓释药物。此外,大部分栓塞剂与显影剂无法紧密交联,术中或术后容易出现栓塞剂和显影剂分离,无法有效监测栓塞剂的位置,导致栓塞不完全或异位栓塞。
发明内容
本发明的目的在于克服上述现有技术的不足之处而提供一种血管栓塞剂及其制备方法与应用,所述血管栓塞剂在血管内具有稳定的机械性能,出色的生物相容性,良好的弥散性,易输送至微血管以及形状复杂的靶血管,不粘管,可有效地装载药物。所述血管栓塞剂与显影剂紧密交联,不会产生影像学伪影。
为实现上述目的,本发明所采取的技术方案为:
一种血管栓塞剂的制备方法,其特征在于,包括如下步骤:
(1)将1,2-二硫戊环类化合物、多酚类化合物、生物碱溶解于有机溶剂A中,得到混合溶液A;
(2)将所述混合溶液A密封后置于70℃以上的环境中反应5~12h,得到混合溶液B;
(3)将所述混合溶液B冷却至室温,向其中加入有机溶剂B进行稀释,得到所述血管栓塞剂。
1,2-二硫戊环类化合物与多酚类化合物可通过迈克尔加成反应将1,2-二硫戊环类化合物接枝到多酚类化合物的苯环上,形成C-S键,1,2-二硫戊环类化合物上的羧基等基团能与多酚类化合物的酚羟基、羧基或者氨基形成氢键;另外,生物碱既可以中和体系中多余的氢离子,降低产物的细胞毒性、避免产物刺激血管壁,又能通过氢键的作用与1,2-二硫戊环类化合物和多酚类化合物增强凝胶的交联密度,提高栓塞效果。将所述血管栓塞剂注射到生理液(如血液等)以及水溶液中,可以快速形成凝胶。
优选地,所述有机溶剂A、有机溶剂B分别为二甲基亚砜(DMSO)、乙醇中的至少一种,所述有机溶剂A和有机溶剂B相同或不同。进一步优选地,所述有机溶剂A和有机溶剂B为二甲基亚砜,与其他有机溶剂相比,二甲基亚砜对血管的刺激更小。
优选地,所述步骤(1)中,1,2-二硫戊环类化合物、多酚类化合物、生物碱的质量比为(0.05~1):(0.0001~1):(0.01~1);所述有机溶剂A与混合溶液A的质量比为(2~4):10;所述步骤(3)中,有机溶剂B与血管栓塞剂的质量比为(1~5.8):10。进一步优选地,所述步骤(1)中,1,2-二硫戊环类化合物、多酚类化合物、生物碱的质量比为0.6:(0.025~0.1):(0~0.3)。通过对各成分的配比作上述优选,可以保证反应能够充分进行,血管栓塞剂注射入生理液中可以快速成胶,具有良好的栓塞效果。
进一步优选地,所述步骤(1)中,1,2-二硫戊环类化合物、多酚类化合物、生物碱的质量比为0.6:0.05:0.3。在满足上述配比的情况下,制备的血管栓塞剂可快速固化,不易粘管,具有优良的操作性,并且具有较好的机械性能,可以对血管形成良好的堵塞作用。
优选地,所述步骤(2)中,混合溶液A在90℃下反应10h,在上述条件下制备的反应产物具有稳定的机械性能、较低的粘度和合适的成胶时间等特点,并且反应效率高。
优选地,所述1,2-二硫戊环类化合物为硫辛酸、芦笋酸、二硫吡咯酮类抗生素、kottamide E中的至少一种;所述多酚类化合物为单宁酸、没食子酸、咖啡酸、儿茶酚、多巴胺、聚多巴胺、白藜芦醇、槲皮素、姜黄素、绿原酸、异黄酮、花青素、可可多酚、柠檬黄素、儿茶素、芸香苷中的至少一种;所述生物碱为氨丁三醇、麻黄碱、益母草碱、金鸡纳碱中的至少一种。
进一步优选地,所述1,2-二硫戊环类化合物为硫辛酸,所述多酚类化合物为单宁酸,所述生物碱为氨丁三醇。上述成分具有良好的生物相容性,并且反应效率高,具有较高的经济效益。
优选地,所述步骤(3)中,稀释后,加入显影剂,所述显影剂的加入量为血管栓塞剂质量的10wt%~80wt%;所述显影剂为熔点在35℃以下的液态金属或钽粉微颗粒。加入上述显影剂可以得到不透X射线的血管栓塞剂,有利于手术中和术后检测血管栓塞剂的位置。
进一步优选地,所述显影剂的加入量为血管栓塞剂的30wt%,所述显影剂为镓铟合金。所述显影剂能通过静电作用或螯合作用与1,2-二硫戊环类化合物和多酚类化合物的反应产物牢固且稳定的结合,在使用或者长时间放置过程中不会和栓塞剂发生脱离。因此能在手术过程中和手术后对血管栓塞剂实现精准定位。
此外,本发明还公开了一种由上述方法制备而成的血管栓塞剂,所述血管栓塞剂在制备药物载体中的应用,并且本发明还公开了所述血管栓塞剂在人体各脏器动静脉出血性病变、动脉瘤、动静脉畸形以及装载化疗药物/靶向药物/免疫抑制剂后用于肿瘤的化疗栓塞治疗中的应用。
相比于现有技术,本发明的有益效果为:
(1)本发明以1,2-二硫戊环类化合物、多酚类化合物、生物碱为主要原料制备的血管栓塞剂在注射入生理液(如血液等)或水溶液中后具有适中的固化时间以及粘度,操作性较好,凝胶不易粘管,易于栓塞手术后拔管。
(2)本发明所述血管栓塞剂固化后具有较好的机械强度和栓塞压力,栓塞效果优异。
(3)本发明选用的制备原料具有良好的生物相容性,制备的血管栓塞剂具有优异的弥散性,可弥散至微血管和形状复杂的靶血管。
(4)本发明将能通过静电作用或螯合作用与1,2-二硫戊环类化合物和酚类化合物的反应产物结合的液态金属或钽粉微颗粒作为显影剂。不仅有利于术中监测栓塞剂的位置,而且减轻了影像学伪影,有利于介入术后的疗效监测。
(5)本发明所述血管栓塞剂可适用于治疗人体各脏器出血性病变、动脉瘤、动静脉畸形,用于良恶性肿瘤的供血动脉栓塞,以及有效装载及缓释化疗药物(如阿霉素、顺铂、卡铂、洛铂、雷替曲塞、吉西他滨、5-氟尿嘧啶、伊立替康、博来霉素、长春西汀中的至少一种)、靶向药物(如索拉菲尼(sorafenib)、仑伐替尼(lenvatinib)、瑞戈非尼(regorafenib)、卡博替尼(cabozantinib)、阿帕替尼、安罗替尼中的至少一种)以及免疫抑制剂(如阿替利珠单抗(atezolizumab),可瑞达(keytruda)、纳武利尤单抗(nivolumab)、卡瑞利珠单抗、信迪利单抗中的至少一种)等后用于多种恶性肿瘤的化疗栓塞治疗。
附图说明
图1为以1,2-二硫戊环类化合物和多酚类化合物为主要原料制备血管栓塞剂的示意图;
图2为以硫辛酸和单宁酸为主要原料制备血管栓塞剂的示意图;
图3为硫辛酸和聚(硫辛酸-单宁酸)的拉曼光谱图;
图4为栓塞剂注射压力测试图,其中,A为测试示意图,B为不同栓塞剂在1.7F微导管中的测试结果图,C为不同导管规格图,D为PLA-TA-Tro-Ga栓塞剂在不同导管中的注射压力测试结果图;
图5为体外栓塞压力测试图,其中,A为测试示意图,B为不同栓塞剂的测试结果图;
图6为生物相容性测试结果图,其中,A为不同实验组溶血照片,B为溶血率测试结果图,C为L929细胞与不同栓塞剂共同孵育后的活/死细胞染色图,D为细胞存活率测试图;
图7为体外药物释放曲线图,A~C分别为装载阿霉素、索拉菲尼、阿替利珠单抗的释放曲线图;
图8为体内外X光成像图,其中,A为装有血管栓塞剂的注射器的X光成像图,B为含有血管栓塞剂的兔耳动脉及分支血管的X光成像图,C为含有血管栓塞剂的肾动脉及分支血管的X光成像图;
图9为兔肾动脉和肾实质栓塞前后对比图,其中,A为兔肾动脉栓塞前后光学图,B为兔肾动脉栓塞前后彩色多普勒超声成像图,C为肾实质栓塞前后二维灰阶超声成像图,D为肾实质栓塞前后彩色多普勒超声成像图;
图10为兔股动脉栓塞前后对比图,其中,A为兔股动脉栓塞前光学图,B为兔股动脉栓塞前彩色多普勒超声成像图,C为兔股动脉栓塞后光学图,D为兔股动脉栓塞后彩色多普勒超声成像图;
图11为实施例3的制备示意图;
图12为实施例4的制备示意图;
图13为实施例5的制备示意图;
图14为实施例6的制备示意图;
图15为实施例7的制备示意图;
图16为实施例8的制备示意图;
图17为实施例9的制备示意图;
图18为实施例10的制备示意图;
图19为实施例11的制备示意图;
图20为实施例12的制备示意图;
图21为实施例13的制备示意图;
图22为实施例14的制备示意图;
图23为实施例15的制备示意图;
图24为实施例16的制备示意图;
图25为实施例17的制备示意图。
具体实施方式
为更好地说明本发明的目的、技术方案和优点,下面将结合附图和具体实施例对本发明作进一步说明。
实施例1
本发明所述血管栓塞剂的制备方法的一种实施例,本实施例所述血管栓塞剂的制备方法如下,各成分的质量比如表1所示:
(1)将不同质量配比的硫辛酸、单宁酸、氨丁三醇粉末溶解于DMSO中,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将混合溶液B冷却至室温,加入DMSO稀释,得到所述血管栓塞剂,记为PLA-TA-Tro(DMSO)。
将所述PLA-TA-Tro(DMSO)与模拟生理液混合,形成PLA-TA-Tro水凝胶,记为PLA-TA-Tro(Gel)。
图1为以1,2-二硫戊环类化合物和多酚类化合物为主要原料制备血管栓塞剂的示意图;图2为以硫辛酸和单宁酸为主要原料制备血管栓塞剂的示意图,从图中可以看到,硫辛酸和单宁酸通过迈克尔加成反应生成含C-S共价键以及氢键的化合物,与生物碱、DMSO组成本发明所述血管栓塞剂,将所述血管栓塞剂注射入生理液(如血液等)或水中,PLA-TA-Tro(DMSO)能在疏水作用等作用的驱动下形成致密的三维交联网络,形成PLA-TA-Tro(Gel)。
对不同原料配比下制备的PLA-TA-Tro(DMSO)的固化时间,PLA-TA-Tro(Gel)的pH值、粘度、储能模量进行测试,测试结果如表1所示。
表1
备注:表中“—”表示无法成胶。
由表1可知,样品22具有最优的综合性能,PLA-TA-Tro(DMSO)具有适中的固化时间,PLA-TA-Tro(Gel)具有合适的粘度,所述血管栓塞剂的可操作性、使用性较好,不易粘管,栓塞后易拔管。样品5、样品10、样品15、样品20中由于氨丁三醇浓度过高,其与聚硫辛酸上的羧基形成较强的静电作用,阻止了聚合物之间氢键的形成,导致无法成胶;样品25中DMSO浓度过高,聚合物的浓度及相互作用力显著下降,导致其无法通过氢键交联成胶。
图3为硫辛酸单体和样品22血管栓塞剂(硫辛酸和聚(硫辛酸-单宁酸))的拉曼光谱图,其中,510cm-1对应S-S键,676cm-1处对应C-S键。该结果表明1,2-二硫戊环类化合物与多酚类化合物接枝成功。
实施例2
本发明所述血管栓塞剂的制备方法的一种实施例,本实施例所述血管栓塞剂的制备方法为:将实施例1中样品22所述血管栓塞剂PLA-TA-Tro(DMSO)与镓铟锡合金按不同配比混合,得到血管栓塞剂PLA-TA-Tro-Ga(DMSO),两种成分的配比如表2所示。将所述PLA-TA-Tro-Ga(DMSO)注射至模拟生理液(1L的去离子水中加入8.035g氯化钠、0.355g碳酸氢钠、0.225g氯化钾、0.231g磷酸氢二钾、0.311g六水合氯化镁、39mL 1M盐酸、0.292g氯化钙、0.072g硫酸钠和6.118g氨丁三醇)中,形成PLA-TA-Tro-Ga水凝胶,记为PLA-TA-Tro-Ga(Gel)。
对不同原料配比下制备的PLA-TA-Tro-Ga(DMSO)的固化时间,PLA-TA-Tro-Ga(Gel)的粘度、储能模量以及CT值进行测试,测试结果如表2所示。
表2
备注:表中“—”表示无法成胶。
由表2可知,当显影剂的加入量为所述血管栓塞剂PLA-TA-Tro-Ga(DMSO)质量的30wt%时,具有最优的综合性能。PLA-TA-Tro-Ga(DMSO)的固化时间为9min,形成的PLA-TA-Tro-Ga(Gel)的粘度适中,并且还具有极高的储能模量,栓塞效果优异,而且CT值可达1000Hu,治疗过程中易于追踪。样品35中液态金属浓度过高,聚合物的浓度及相互作用力显著下降,导致其无法通过氢键交联成胶。
以下性能测试实验中使用的PLA-TA-Tro-Ga(DMSO)均为样品32所述血管栓塞剂PLA-TA-Tro-Ga(DMSO)。
栓塞剂的注射压力测试:将1mL螺口注射器按图4A放置在自制的测试仪器上,注射器上端跟上压板接触,下端被夹具垂直固定并连接不同规格的导管。1)分别将1mL PLA-TA-Tro-Ga(DMSO)、Onyx、碘化油、生理盐水添加到注射器内,下端连接1.7F微导管;然后,使用上压板匀速地(流量:2mL/min)按压注射器,同时记录上压板压力的变化。结果如图4B所示,碘化油、PLA-TA-Tro-Ga(DMSO)、Onyx、生理盐水的注射压力依次降低,说明PLA-TA-Tro-Ga(DMSO)的注射还是较为容易的。2)将1mL PLA-TA-Tro-Ga(DMSO)添加到注射器内,下端连接不同规格的导管(图4C);然后,使用上压板匀速地(流量:2mL/min)按压注射器,同时记录上压板压力的变化,结果如图4D所示,注射压力随着微导管直径的增加而降低。综上,PLA-TA-Tro-Ga(DMSO)容易通过导管被注射,具有优良的使用性能。
体外栓塞实验:将注射泵、注射器、压力计、猪的主动脉(内径:6mm)、聚二甲基硅氧烷(Polydimethylsiloxane,PDMS)管道(内径:6mm)按照图5A连接,并在整个管道内充满37℃的抗凝血液,再将猪的主动脉和PDMS管道浸泡在37℃的抗凝血液中。随后,分别将PLA-TA-Tro-Ga(DMSO)(1mL)、Onyx(1mL)、弹簧圈(1枚,6mm*6mm)通过5F微导管(内径:1.7mm)注入猪主动脉内。取出导管后(血管栓塞剂已形成凝胶),以80mL/min的流量推送抗凝血液直至血管栓塞剂凝胶PLA-TA-Tro-Ga(Gel)从血管中排出,同时利用压力表记录体系压力的变化,最大值记为栓塞剂的栓塞压力。由图5B可知,相对于弹簧圈和Onyx,PLA-TA-Tro-Ga(Gel)具有更大的栓塞压力,能有利于栓塞具有较大血压的动脉血管。
溶血实验:通过离心(200×g,10min)收集兔全血红细胞,用生理盐水稀释至5%(v/v)。分别将50μL PLA-TA-Tro-Ga(DMSO)、PLA-TA-Tro(DMSO)、DMSO、生理盐水(阴性对照)和去离子水(阳性对照)加到1mL上述血细胞溶液中,并在37℃孵育24h。将红细胞悬液离心(500×g,15min)后,将上层清液转移到96孔板,使用酶标仪测试溶液在540nm处的吸光度。溶血率计算如下:溶血率(%)=(As-An)/(Ad-An)×100%(As、An和Ad分别为样品、生理盐水和去离子水组的吸光度)。为保证数据的可靠性,每组实验重复3次。结果如图6所示,PLA-TA-Tro-Ga(DMSO)溶血率小于5%,满足生物材料的使用要求。
细胞毒性实验:将L929细胞加入12孔板(25000个/孔),并在37℃培育箱孵育12h。然后,分别将50mg PLA-TA-Tro-Ga(Gel)、PLA-TA-Tro(Gel)、Ga加入含有细胞的孔中,将不添加任何材料的组作为阳性对照。孵育24h后,用活/死细胞染色法评估细胞活力。为保证数据的可靠性,每组实验重复3次。结果如图6所示,所有组别的细胞存活率均大于98%,且细胞呈现正常铺展的梭形。该结果说明,凝胶无细胞毒性,具有良好的细胞生物相容性。
阿霉素缓释能力:测定阿霉素溶液的紫外-可见光谱,将最大吸光度所对应的波长值(480nm)作为其特征波长。配置不同浓度的阿霉素溶液,并测试它们在480nm波长下的吸光度,绘制吸光度-浓度标准曲线。将10mg阿霉素溶解于2mL PLA-TA-Tro-Ga(DMSO)中,于37℃条件下孵育24h后,将上述溶液注射于20mL的磷酸缓冲盐溶液(PBS)中。在设置的时间点取200μL上清液,测试其在480nm波长下的吸光度,根据吸光度-浓度标准曲线计算出溶液里阿霉素的浓度。将载有阿霉素的碘化油作为对照实验。结果如图7A所示,PLA-TA-Tro-Ga(Gel)可以缓慢地释放阿霉素,在第35天才达到近100%的释放,而碘化油在第3天就达到了近100%的释放。该结果表明,本发明所述血管栓塞剂可以负载阿霉素等化疗药物,并具有良好的缓释效果。
索拉菲尼释放曲线:测定索拉菲尼溶液的紫外-可见光谱,将最大吸光度所对应的波长值(265nm)作为其特征波长。配置不同浓度的索拉菲尼溶液,并测试它们在265nm波长下的吸光度,绘制吸光度-浓度标准曲线。然后,将200mg索拉菲尼溶解于2mL PLA-TA-Tro-Ga(DMSO)中,于37℃条件下孵育24h后,将上述溶液注射于20mL的磷酸缓冲盐溶液(PBS)中,特定时间点取200μL上清液,测试其265nm吸光度,根据吸光度-浓度标准曲线计算出溶液里索拉菲尼的浓度。将载有索拉菲尼的碘化油作为对照实验。结果如图7B所示,PLA-TA-Tro-Ga(Gel)能缓慢地释放阿霉素,在第21天才达到近100%的释放,而碘化油在第3天就达到了近100%的释放。上述结果表明,本发明所述血管栓塞剂对索拉菲尼等靶向药物也具有良好的缓释效果。
阿替利珠单抗释放曲线:采用酶联免疫吸附实验(Enzyme Linked ImmunosorbentAssay,ELISA,R&D,DY1086)试剂盒测定单抗的浓度。利用酶标仪检测试剂盒内标准品在450nm处的吸光度,绘制吸光度-浓度标准曲线。分别将0.1μg程序性细胞死亡蛋白1(Programmed cell death protein 1,PD-1)依次加入96孔板中。取60mg阿替利珠单抗溶解于2mL PLA-TA-Tro-Ga(DMSO)中,于37℃条件下孵育24h后,将上述装载阿替利珠单抗的混合溶液注射于20mL的磷酸缓冲盐溶液(PBS)中。在设置的时间点取200μL上清液并用PBS稀释1000倍,再将500μL上述稀释溶液加入装有PD-1蛋白的96孔板中。随后,加入PeroxidaseAffinipure Goat Anti-human IgG二抗,利用3,3',5,5'-四甲基联苯胺(3,3',5,5'-Tetramethylbenzidine,TMB)染色。最后利用酶标仪于450nm处读取吸光度,再根据吸光度-浓度标准曲线计算出溶液里阿替利珠单抗的浓度。将载有阿替利珠单抗的碘化油作为对照实验。结果如图7C所示,PLA-TA-Tro-Ga(Gel)能缓慢地释放阿替利珠单抗,在第25天才达到近100%的释放,而碘化油在第3天就达到了近100%的释放。上述结果表明,本发明所述血管栓塞剂可以负载阿替利珠单抗等免疫抑制剂,并且具有良好的药物缓释性能。
体外X光成像实验:使用1mL注射器抽取1mL PLA-TA-Tro-Ga(DMSO)进行X光成像,如图8A所示,PLA-TA-Tro-Ga(DMSO)X线下呈均匀一致高密度像、无伪影。
体内X光成像实验:利用注射器分别向兔耳动脉和肾动脉分别注入1mL和1.5mLPLA-TA-Tro-Ga(DMSO),在X线下可以清楚地看到充满动脉和分支血管的PLA-TA-Tro-Ga(DMSO),且无伪影(图8B、8C)。
兔肾动脉栓塞实验:将实验兔全麻、固定、消毒铺巾后,沿着正中腹部切开皮肤、肌肉、筋膜,逐层钝性分离出肾动脉,并用彩色多普勒超声仪对其进行成像观察。随后,向肾动脉注入1.5mL PLA-TA-Tro-Ga(DMSO)。1分钟后,将针头拔出,针头未见凝胶粘连,穿刺点未见出血。说明该液体栓塞剂不粘管。随后,用彩色多普勒超声仪对栓塞部位进行成像观察。如图9所示,栓塞后,肾动脉血流信号消失,肾实质内多发散在高回声。该结果说明PLA-TA-Tro-Ga(DMSO)凝胶后能成功栓塞实验兔的肾动脉。
兔股动脉栓塞:实验兔全麻、固定、左侧腹股沟区消毒铺巾后,切开皮肤及肌肉,逐层钝性分离出股动脉,并用彩色多普勒超声仪对其进行成像观察。随后,向股动脉内注入1mL PLA-TA-Tro-Ga(DMSO)。1分钟后,将针头拔出,针头未见凝胶粘连,穿刺点未见出血,说明该液体栓塞剂不粘管。随后,用彩色多普勒超声仪对栓塞部位进行成像观察。如图10所示,栓塞后,股动脉血流信号消失。该结果说明PLA-TA-Tro-Ga(DMSO)凝胶后能成功栓塞实验兔的股动脉。
实施例3
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.2g硫辛酸、0.8g没食子酸和0.6g氨丁三醇粉末溶解于0.6g的DMSO中,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃条件下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入2.5g DMSO稀释,最后,加入1.5g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为10min,粘度为89mPa.s,储能模量为470kPa。本实施例所述血管栓塞剂的制备示意图如图11所示。
实施例4
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)1.2g硫辛酸、0.5g咖啡酸和0.6g氨丁三醇粉末溶解于0.6g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入2.5g DMSO进行稀释,最后,加入1.0g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为9min,粘度为92mPa.s,储能模量为480kPa。本实施例所述血管栓塞剂的制备示意图如图12所示。
实施例5
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)1.2g硫辛酸、0.8g儿茶酚和0.6g氨丁三醇粉末溶解于0.6g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入1.5g DMSO进行稀释,最后,加入1.2g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为11min,粘度为80mPa.s,储能模量为465kPa。本实施例所述血管栓塞剂的制备示意图如图13所示。
实施例6
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)1.2g硫辛酸、1.0g多巴胺和0.6g氨丁三醇粉末溶解于0.6g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入2.5g DMSO进行稀释,最后,加入1.6g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为9min,粘度为82mPa.s,储能模量为493kPa。本实施例所述血管栓塞剂的制备示意图如图14所示。
实施例7
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.2g硫辛酸、0.2g聚多巴胺和0.6g氨丁三醇粉末溶解于0.4g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入1.5g DMSO进行稀释,最后,加入1.2g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为12min,粘度为77mPa.s,储能模量为520kPa。本实施例所述血管栓塞剂的制备示意图如图15所示。
实施例8
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.2g硫辛酸、0.2g白藜芦醇和0.6g氨丁三醇粉末溶解于0.4g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入1.5g DMSO进行稀释,最后,加入1.0g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为10min,粘度为86mPa.s,储能模量为489kPa。本实施例所述血管栓塞剂的制备示意图如图16所示。
实施例9
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.2g硫辛酸、0.6g槲皮素和0.6g氨丁三醇粉末溶解于0.5g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入2.0g DMSO进行稀释,最后,加入1.2g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为11min,粘度为76mPa.s,储能模量为490kPa。本实施例所述血管栓塞剂的制备示意图如图17所示。
实施例10
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.4g芦笋酸、0.1g单宁酸和0.5g氨丁三醇粉末溶解于0.4g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入2.0g DMSO进行稀释,最后,加入1.0g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为9min,粘度为80mPa.s,储能模量为477kPa。本实施例所述血管栓塞剂的制备示意图如图18所示。
实施例11
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.2g芦笋酸、1.0g没食子酸和0.5g氨丁三醇粉末溶解于0.6g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入2.0g DMSO进行稀释,最后,加入1.6g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为8min,粘度为80mPa.s,储能模量为466kPa。本实施例所述血管栓塞剂的制备示意图如图19所示。
实施例12
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.2g芦笋酸、1.0g咖啡酸和0.5g氨丁三醇粉末溶解于0.5g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入2.5g DMSO进行稀释,最后,加入1.8g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为9min,粘度为77mPa.s,储能模量为482kPa。本实施例所述血管栓塞剂的制备示意图如图20所示。
实施例13
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.4g芦笋酸、1.0g儿茶酚和0.5g氨丁三醇粉末溶解于0.6g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入3.0g DMSO进行稀释,最后,加入1.8g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为10min,粘度为86mPa.s,储能模量为489kPa。本实施例所述血管栓塞剂的制备示意图如图21所示。
实施例14
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.4g芦笋酸、0.6g多巴胺和0.5g氨丁三醇粉末溶解于0.5g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入2.5g DMSO进行稀释,最后,加入1.2g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为12min,粘度为65mPa.s,储能模量为412kPa。本实施例所述血管栓塞剂的制备示意图如图22所示。
实施例15
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.4g芦笋酸、0.1g聚多巴胺和0.5g氨丁三醇粉末溶解于0.5g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入2.0g DMSO进行稀释,最后,加入1.0g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为9min,粘度为78mPa.s,储能模量为482kPa。本实施例所述血管栓塞剂的制备示意图如图23所示。
实施例16
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.4g芦笋酸、0.5g白藜芦醇和0.5g氨丁三醇粉末溶解于0.5g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入2.5g DMSO进行稀释,最后,加入1.2g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为12min,粘度为65mPa.s,储能模量为412kPa。本实施例所述血管栓塞剂的制备示意图如图24所示。
实施例17
本发明所述血管栓塞剂的一种实施例,本实施例所述血管栓塞剂的制备方法如下:
(1)将1.4g芦笋酸、0.3g槲皮素和0.5g氨丁三醇粉末溶解于0.4g的DMSO后,得到混合溶液A;
(2)将所述混合溶液A密封后置于90℃下反应10h,得到混合溶液B;
(3)将所述混合溶液B取出,冷却至室温,加入2.0g DMSO进行稀释,最后,加入1.0g显影剂镓铟锡合金,得到所述血管栓塞剂。所得到的血管栓塞剂固化时间为10min,粘度为88mPa.s,储能模量为378kPa。本实施例所述血管栓塞剂的制备示意图如图25所示。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,但并不脱离本发明技术方案的实质和范围。
Claims (10)
1.一种血管栓塞剂的制备方法,其特征在于,包括如下步骤:
(1)将1,2-二硫戊环类化合物、多酚类化合物、生物碱溶解于有机溶剂A中,得到混合溶液A;
(2)将所述混合溶液A密封后置于70℃以上的环境中反应5~12h,得到混合溶液B;
(3)将所述混合溶液B冷却至室温,向其中加入有机溶剂B进行稀释,得到所述血管栓塞剂。
2.如权利要求1所述的制备方法,其特征在于,所述有机溶剂A、有机溶剂B分别为二甲基亚砜、乙醇中的至少一种,所述有机溶剂A和有机溶剂B相同或不同。
3.如权利要求1所述的制备方法,其特征在于,所述步骤(1)中,1,2-二硫戊环类化合物、多酚类化合物、生物碱的质量比为(0.05~1):(0.0001~1):(0.01~1);所述有机溶剂A与混合溶液A的质量比为(2~4):10;所述步骤(3)中,有机溶剂B与血管栓塞剂的质量比为(1~5.8):10。
4.如权利要求3所述的制备方法,其特征在于,所述步骤(1)中,1,2-二硫戊环类化合物、多酚类化合物、生物碱的质量比为0.6:(0.025~0.1):(0~0.3)。
5.如权利要求1所述的制备方法,其特征在于,所述1,2-二硫戊环类化合物为硫辛酸、芦笋酸、二硫吡咯酮类抗生素、kottamide E中的至少一种;所述多酚类化合物为单宁酸、没食子酸、咖啡酸、儿茶酚、多巴胺、聚多巴胺、白藜芦醇、槲皮素、姜黄素、绿原酸、异黄酮、花青素、可可多酚、柠檬黄素、儿茶素、芸香苷中的至少一种;所述生物碱为氨丁三醇、麻黄碱、益母草碱、金鸡纳碱中的至少一种。
6.如权利要求5所述的制备方法,其特征在于,所述1,2-二硫戊环类化合物为硫辛酸,所述多酚类化合物为单宁酸,所述生物碱为氨丁三醇,所述有机溶剂A和有机溶剂B为二甲基亚砜。
7.如权利要求1所述的制备方法,其特征在于,所述步骤(3)中,稀释结束后,加入显影剂,所述显影剂的加入量为血管栓塞剂质量的10wt%~80wt%;所述显影剂为熔点在35℃以下的液态金属或钽粉微颗粒。
8.如权利要求7所述的制备方法,其特征在于,所述显影剂的加入量为血管栓塞剂的30wt%,所述显影剂为镓铟合金。
9.一种血管栓塞剂,其特征在于,所述血管栓塞剂由如权利要求1~8任一项所述方法制备而成。
10.一种如权利要求9所述血管栓塞剂在制备药物载体中的应用。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211019192.1A CN115463246B (zh) | 2022-08-24 | 2022-08-24 | 一种血管栓塞剂及其制备方法与应用 |
PCT/CN2023/114026 WO2024041484A1 (zh) | 2022-08-24 | 2023-08-21 | 一种血管栓塞剂及其制备方法与应用 |
AU2023329278A AU2023329278A1 (en) | 2022-08-24 | 2023-08-21 | Vascular embolic agent, method for preparing same and use thereof |
CA3237741A CA3237741A1 (en) | 2022-08-24 | 2023-08-21 | Vascular embolic agent, method for preparing same and use thereof |
KR1020247015168A KR20240073977A (ko) | 2022-08-24 | 2023-08-21 | 혈관 색전제, 이의 제조 방법 및 이의 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211019192.1A CN115463246B (zh) | 2022-08-24 | 2022-08-24 | 一种血管栓塞剂及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115463246A true CN115463246A (zh) | 2022-12-13 |
CN115463246B CN115463246B (zh) | 2023-06-20 |
Family
ID=84365786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211019192.1A Active CN115463246B (zh) | 2022-08-24 | 2022-08-24 | 一种血管栓塞剂及其制备方法与应用 |
Country Status (5)
Country | Link |
---|---|
KR (1) | KR20240073977A (zh) |
CN (1) | CN115463246B (zh) |
AU (1) | AU2023329278A1 (zh) |
CA (1) | CA3237741A1 (zh) |
WO (1) | WO2024041484A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117338703A (zh) * | 2023-12-05 | 2024-01-05 | 中山大学附属第五医院 | 凝胶靶向递送系统及其制备方法和应用 |
WO2024041484A1 (zh) * | 2022-08-24 | 2024-02-29 | 中山大学附属第五医院 | 一种血管栓塞剂及其制备方法与应用 |
CN117982713A (zh) * | 2024-03-18 | 2024-05-07 | 中山大学附属第五医院 | 血管内栓塞组合物及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101822635A (zh) * | 2010-04-15 | 2010-09-08 | 中山大学 | 一种新型的原位液晶血管栓塞剂 |
CN107899064A (zh) * | 2017-10-27 | 2018-04-13 | 华威(深圳)医疗器械有限责任公司 | 一种可载药且兼具显影性的液体栓塞剂的制备方法及其用途 |
US20200163885A1 (en) * | 2017-07-25 | 2020-05-28 | Lemonex Inc. | Composition for delivering physiologically active ingredients into blood vessel |
CN111557898A (zh) * | 2020-06-22 | 2020-08-21 | 珠海神平医疗有限公司 | 一种栓塞剂及其制备方法 |
WO2021143751A1 (zh) * | 2020-01-14 | 2021-07-22 | 中国科学院上海药物研究所 | 可注射长效镇痛药物组合物及其制备方法和用途 |
CN114522256A (zh) * | 2021-12-27 | 2022-05-24 | 中山大学附属第五医院 | 一种聚羟基脂肪酸酯载药放疗微球及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005013810A2 (en) * | 2003-08-07 | 2005-02-17 | University Of Florida | Biodegradable embolic agents |
CN106334213B (zh) * | 2016-08-31 | 2019-07-26 | 安疗生命科学(武汉)有限公司 | 一种血管栓塞材料、其制备方法及在药物制备中的用途 |
CA3191526A1 (en) * | 2020-09-04 | 2022-03-10 | Suresh S. Pai | Liquid embolic compositions with controlled release of radiopaque and therapeutic compounds and methods of using the same |
CN113621342B (zh) * | 2021-08-27 | 2022-08-26 | 四川大学 | 一种无溶剂粘结剂及其制备方法与应用 |
CN115463246B (zh) * | 2022-08-24 | 2023-06-20 | 中山大学附属第五医院 | 一种血管栓塞剂及其制备方法与应用 |
-
2022
- 2022-08-24 CN CN202211019192.1A patent/CN115463246B/zh active Active
-
2023
- 2023-08-21 CA CA3237741A patent/CA3237741A1/en active Pending
- 2023-08-21 WO PCT/CN2023/114026 patent/WO2024041484A1/zh active Application Filing
- 2023-08-21 KR KR1020247015168A patent/KR20240073977A/ko unknown
- 2023-08-21 AU AU2023329278A patent/AU2023329278A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101822635A (zh) * | 2010-04-15 | 2010-09-08 | 中山大学 | 一种新型的原位液晶血管栓塞剂 |
US20200163885A1 (en) * | 2017-07-25 | 2020-05-28 | Lemonex Inc. | Composition for delivering physiologically active ingredients into blood vessel |
CN107899064A (zh) * | 2017-10-27 | 2018-04-13 | 华威(深圳)医疗器械有限责任公司 | 一种可载药且兼具显影性的液体栓塞剂的制备方法及其用途 |
WO2021143751A1 (zh) * | 2020-01-14 | 2021-07-22 | 中国科学院上海药物研究所 | 可注射长效镇痛药物组合物及其制备方法和用途 |
CN111557898A (zh) * | 2020-06-22 | 2020-08-21 | 珠海神平医疗有限公司 | 一种栓塞剂及其制备方法 |
CN114522256A (zh) * | 2021-12-27 | 2022-05-24 | 中山大学附属第五医院 | 一种聚羟基脂肪酸酯载药放疗微球及其制备方法和应用 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024041484A1 (zh) * | 2022-08-24 | 2024-02-29 | 中山大学附属第五医院 | 一种血管栓塞剂及其制备方法与应用 |
CN117338703A (zh) * | 2023-12-05 | 2024-01-05 | 中山大学附属第五医院 | 凝胶靶向递送系统及其制备方法和应用 |
CN117338703B (zh) * | 2023-12-05 | 2024-03-08 | 中山大学附属第五医院 | 凝胶靶向递送系统及其制备方法和应用 |
CN117982713A (zh) * | 2024-03-18 | 2024-05-07 | 中山大学附属第五医院 | 血管内栓塞组合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20240073977A (ko) | 2024-05-27 |
CN115463246B (zh) | 2023-06-20 |
AU2023329278A1 (en) | 2024-05-23 |
CA3237741A1 (en) | 2024-02-29 |
WO2024041484A1 (zh) | 2024-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115463246B (zh) | 一种血管栓塞剂及其制备方法与应用 | |
CN102232098B (zh) | 用于治疗血管栓塞形成的微球 | |
JP4885866B2 (ja) | 治療適用および/または診断適用のための充填可能なポリホスファゼン含有粒子、ならびにその調製方法および使用方法 | |
US6531111B1 (en) | High viscosity embolizing compositions | |
Yang et al. | Development of PVA-based microsphere as a potential embolization agent | |
US5888546A (en) | Embolic material for endovascular occlusion of abnormal vasculature and method for using the same | |
US9114162B2 (en) | Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same | |
US9844597B2 (en) | Biocompatible in situ hydrogel | |
EP2545906B1 (en) | Colour-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and colour-coded syringe comprising the same | |
EP0843560A1 (en) | Cellulose diacetate compositions for use in embolizing blood vessels | |
US20050131458A1 (en) | Biodegradable embolic agents | |
EP3756700B1 (en) | Liquid embolic agent composition | |
Klisch et al. | Liquid 2-poly-hydroxyethyl-methacrylate embolization of experimental arteriovenous malformations: feasibility study | |
EP2353624A1 (en) | Embolic material, its process of preparation and its therapeutical uses thereof | |
EP3880724A1 (en) | Polymer for liquid embolic agents and method of obtaining same | |
EP2214718B1 (en) | Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same | |
Legon’kova et al. | In Vivo Studies of a Liquid Embolic Compound | |
Kazekawa et al. | Newly synthesized liquid embolization material for arteriovenous malformation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |